Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 20 Ovarian Neoplasms 19 Fallopian Tube Neoplasms 9 Prostatic Neoplasms 7 Triple Negative Breast Neoplasms 6 Neoplasm Metastasis 6 Small Cell Lung Carcinoma 4 Pancreatic Neoplasms 4 Metastatic Castration-resistant Prostate Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Lung Neoplasms 3 Glioma 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Solid Tumors 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Osteosarcoma 2 Neoplasms 2 Glioblastoma 2 Cholangiocarcinoma 2 Carcinosarcoma 2 Carcinoma, Endometrioid 2 Xanthogranuloma, Juvenile 1 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Advanced Solid Neoplasms × olaparib × Clear all

NCT03742895 2026-05-15

MK-7339-002

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Advanced Solid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡